Houston, Texas
United States
33
2026-05-07
The entities that hold a legal rights for patent applications filed by inventor Yee Cassian:
Cassian Yee from Houston, US has applied for patents for these inventions. The list has both pending applications and granted patents:
PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING MAGE-A4 ANTIGEN AND METHODS OF USE
#2 | 2026-01-08PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING VCY ANTIGEN AND METHODS OF USE
#3 | 2025-10-16METHODS FOR PRODUCTION OF TISSUE RESIDENT MEMORY-LIKE T CELLS AND USE THEREOF
#4 | 2025-09-18PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING NDC80 ANTIGEN AND METHODS OF USE
#5 | 2025-05-08USE OF HISTONE MODIFIERS TO REPROGRAM EFFECTOR T CELLS
#6 | 2025-03-27T CELL RECEPTORS WITH MAGE-B2 SPECIFICITY AND USES THEREOF
#7 | 2025-03-20T CELL RECEPTORS FOR IMMUNOTHERAPY
#8 | 2025-03-06PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING FANCI, RAD51, AND PBK ANTIGENS AND METHODS OF USE
#9 | 2024-09-05PEPTIDES AND ENGINEERED T CELL RECEPTORS TARGETING SARS-COV-2 ANTIGENS AND METHODS OF USE
#10 | 2024-06-27METHODS AND COMPOSITIONS COMPRISING MHC CLASS I PEPTIDES
#11 | 2024-06-20METHODS AND COMPOSITIONS FOR GENETIC MODIFICATION AND THERAPEUTIC USE OF IMMUNE CELLS
#12 | 2024-04-18HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF
#13 | 2024-01-25METHODS AND COMPOSITIONS COMPRISING MHC CLASS PEPTIDES
#14 | 2024-01-11ENGINEERED T CELL RECEPTORS TARGETING EGFR ANTIGENS AND METHODS OF USE
#15 | 2023-07-20ENGINEERED T CELL RECEPTORS AND METHODS OF USE
#16 | 2023-07-06T CELL RECEPTORS WITH VGLL1 SPECIFICITY AND USES THEREOF
#17 | 2023-06-22ENGINEERED T CELL RECEPTORS AND METHODS OF USE
#18 | 2023-05-11ENGINEERED T CELL RECEPTORS AND METHODS OF USE
#19 | 2023-04-06METHODS FOR EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES AND USE THEREOF
#20 | 2022-12-29HLA RESTRICTED HORMAD1 T CELL RECEPTORS AND USES THEREOF
#21 | 2022-11-24HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOF
#22 | 2022-11-03VCX/Y PEPTIDES AND USE THEREOF
#23 | 2022-03-10ENHANCED GENERATION OF CYTOTOXIC T-LYMPHOCYTES BY IL-21 MEDIATED FOXP3 SUPPRESSION
#24 | 2021-11-25T cell receptors with mage-B2 specificity and uses thereof
#25 | 2021-11-18Methods for production of tissue resident memory-like T cells and use thereof
#26 | 2021-06-24Use of histone modifiers to reprogram effector T cells
#27 | 2021-06-10SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
#28 | 2020-07-30T cell receptors for immunotherapy
#29 | 2020-05-14HLA-restricted VCX/Y peptides and T cell receptors and use thereof
#30 | 2020-02-06HLA-restricted VGLL1 peptides and use thereof in promoting an immune response in a subject
#31 | 2020-01-02Methods of treatment using conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses
#32 | 2019-06-06SLC45A2 PEPTIDES FOR IMMUNOTHERAPY
#33 | 2016-11-03Method of obtaining cytolytic T cells by using mutant tumor epitopes
1696283 ⎘